{"disease":{"id":"progressive-familial-intrahepatic-cholestasis-pfic","name":"progressive familial intrahepatic cholestasis pfic"},"drugs":{"marketed":[{"drug_id":"odevixibat","indication_name":"Pruritus in progressive familial intrahepatic cholestasis (PFIC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bylvay","generic_name":"ODEVIXIBAT","company_name":"Ipsen","drug_phase":"marketed","molecular_target":"Ileal sodium/bile acid cotransporter","drug_class":"Ileal Bile Acid Transporter Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Bylvay works by blocking the ileal sodium/bile acid cotransporter, a protein that helps reabsorb bile acids in the intestines."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03905330","title":"A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04185363","title":"An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07293897","title":"A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT02057718","title":"Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05543187","title":"A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03353454","title":"A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)","phase":"PHASE3","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Mirum Pharmaceuticals, Inc.","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}